Souhaitez-vous accéder aux communiqués récents ?

BALTIMORE, April 10, 2025 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA) announced Peter E. Clark, MD, as the AUA Science and Quality (S&Q) chair-elect. Dr. Clark will...

SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...

– Clinically Meaningful Efficacy Observed on Multiple Assessments – – Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions – MELBOURNE, Australia and SAN FRANCISCO,...

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing...

JAAD: Focal point technology: Controlling treatment depth and pattern of skin injury by a novel highly focused laser.

Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease Education...

MILTON, Del., April 08, 2025 (GLOBE NEWSWIRE) -- In celebration of its 10th consecutive year as the “Official Beer of Record Store Day,” Dogfish Head joins forces with Grateful Dead to launch a...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in...

Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of Neurology A

CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by...